ライフサイエンスコーパス: chemerin

1 t cell tryptase are all potent activators of chemerin.

2 tor chemR23, which binds the chemoattractant chemerin.

3 altered hepatic expression of lipocalin2 or chemerin.

4 , macrophage inflammatory protein 3alpha and chemerin.

5 ctivated endothelial cells specifically bind chemerin.

6 in was used as agonist and complete when the chemerin(149-157) nonapeptide was used as agonist.

7 zation and a much higher potency against the chemerin(149-157) nonapeptide-induced response.

8 tion of a ubiquitous plasma chemoattractant, chemerin, a ligand for the G-protein-coupled receptor CM

9 In addition, chemerin, a natural ligand for CMKLR1, was up-regulated

10 a major serum agonist activity for CMKLR1 as chemerin, a proteolytically activated attractant and the

11 pression datasets we found that the gene for chemerin, a widely expressed endogenous chemoattractant

12 ter analysis demonstrated that both RvE1 and chemerin activate the CD55 promoter.

13 To define the pathophysiologic triggers of chemerin activity, we evaluated the ability of serum- an

14 Chemerin acts as a chemoattractant for monocytes and mac

15 Chemerin also increased expression of the cytoskeletal p

16 Intratumoral injection of chemerin also inhibited tumor growth, suggesting the pot

17 Chemerin, an inflammatory chemokine, with a known role i

18 edite the development of long acting, stable chemerin analogs as candidate therapeutics, we used memb

19 ke 2 (CCRL2) binds leukocyte chemoattractant chemerin and can regulate local levels of the attractant

20 time, tissue-specific expression patterns of Chemerin and ChemR23 in mouse tooth development.

21 The levels of other biochemical parameters, chemerin and IL-1beta, were significantly decreased comp

22 GCF chemerin and IL-6 levels decreased following therapy in

23 Greater values for GCF chemerin and IL-6 levels were found in CP groups than in

24 nked immunosorbent assay was used to measure chemerin and IL-6 levels.

25 P = 0.02), and MMP-13 (r = 0.781, P = 0.01); chemerin and IL-8 (r = 0.913, P <0.01), MMP-8 (r = 0.770

26 raction of macrophages to inflamed tissue by chemerin and in the initiation of resolution of inflamma

27 (t2DM); 2) analyze the relationship between chemerin and interleukin (IL)-6 in periodontally healthy

28 augmenting the expression of IFN-alpha/beta, chemerin and its receptor ChemR23, p-cofilin, LIMK2 and

29 inflammation-associated proteases to cleave chemerin and stimulate CMKLR1-mediated chemotaxis.

30 hat is triggered by two ligands, the peptide chemerin and the eicosapentaenoic acid-derived lipid med

31 the bioactivity of leukocyte chemoattractant chemerin, and further extend the molecular link between

32 Here, we show that the C15 precursor, chemerin, and its receptor, ChemR23, are both upregulate

33 titis and t2DM induced aberrant secretion of chemerin, and non-surgical periodontal therapy influence

34 Recently, coagulation-activated osteopontin, chemerin, and protease-activated receptor signaling, as

35 eceptor 1), the chemoattractant receptor for chemerin, and was abrogated by NK cell depletion.

36 rin levels and its bioactivity, and enhances chemerin- and CMKLR1-dependent lymphocyte/EC adhesion in

37 ddition, administration of neutralizing anti-chemerin antibody before zymosan challenge resulted in a

38 Plasma levels of total chemerin are elevated in CCRL2(-/-) mice and are signifi

39 We further identify chemerin as a natural nonsignaling protein ligand for bo

40 ecific mechanism for the local enrichment of chemerin at inflammatory sites, regulating the recruitme

41 t" or professional chemokine interreceptors, chemerin binding does not trigger ligand internalization

42 In vitro, chemerin binding to CCRL2 on endothelial cells triggers

43 ed for cleavage at Lys(158) or regulation of chemerin bioactivity.

44 ctivation to a similar extent as proteolyzed chemerin, but exhibited reduced activity as a MPhi chemo

45 Activation of chemerin by the serine protease cascades that trigger ra

46 ransmembrane domain receptor ligands such as chemerin can regulate pDC migration.

47 nerate the likely physiologic form of active chemerin, chem157S, and suggested a possible role in mal

48 of plasma, levels of the most potent form of chemerin, chem157S, as well as inactive chem155A, increa

49 er immune cells expressing its receptor, the chemerin chemokine receptor 1 (CMKLR1), to sites of tumo

50 domain-containing protein 2, rs3135500; and chemerin chemokine-like receptor 1, rs1878022) were geno

51 signaling, are phosphorylated in response to Chemerin/ChemR23 signaling in vitro and are expressed in

52 tein S6 (rS6) and Akt, downstream targets of Chemerin/ChemR23 signaling, are phosphorylated in respon

53 onstitute new tools to study the role of the chemerin/ChemR23 system in physiological and pathologica

54 Together, these results suggest roles for Chemerin/ChemR23-mediated DE-DM cell signaling during to

55 Chemerin circulates as an inactive precursor (chem163S),

56 Chemerin circulates as an inactive precursor in blood wh

57 duals, deregulation of a specific adipokine, chemerin, contributes to innate initiation of metaflamma

58 rane and promoted in a more efficient manner chemerin-dependent transmigration of dendritic cells.

59 Collectively, these results show that chemerin-derived peptides may represent a novel therapeu

60 Furthermore, because recent data shows that chemerin-derived peptides possess antiinflammatory prope

61 portant endogenous antiinflammatory role for chemerin-derived species.

62 merin, providing a unique mechanism by which chemerin enhances inflammation.

63 chemotaxis to several chemoattractants like chemerin, fMLF, and MCP-1; and doubled the phagocytic ac

64 d lymphatic murine endothelial cells produce chemerin following retinoic acid stimulation.

65 (FXIa) cleaved chem163S, generating a novel chemerin form, chem162R, as an intermediate product, and

66 can be further processed to the most active chemerin form, providing a molecular link between coagul

67 l proteolytic cleavages resulting in diverse chemerin forms with different levels of activity.

68 we established that a 9-amino acid-tethered chemerin fragment (amino acids 149-157) activates both m

69 including the resistin, angiotensinogen, and chemerin genes, in addition to induction of brown-specif

70 stoma (GBM), we examined the significance of chemerin in GBM biology.

71 sure to DEP plus HDM, elevated the levels of chemerin in the bronchoalveolar lavage fluid of WT mice.

72 The total level of cleaved and noncleaved chemerins in cerebrospinal fluids was approximately 10%

73 enhancement of efficacy as an antagonist of chemerin induced intracellular calcium mobilization and

74 nobody behaves as an efficient antagonist of chemerin-induced chemotaxis of human primary cells.

75 that the nanobodies were able to antagonize chemerin-induced intracellular calcium increase.

76 ansplantable mouse melanoma, tumor-expressed chemerin inhibited in vivo tumor growth without altering

77 ) was mimicked by 2 weeks of ICV infusion of chemerin into rats.

78 Chemerin is a chemoattractant and adipokine that circula

79 Chemerin is a chemoattractant involved in immunity that

80 Chemerin is a chemoattractant involved in innate and ada

81 Chemerin is a chemotactic protein that binds to the G pr

82 mine whether gingival crevicular fluid (GCF) chemerin is a novel predictive marker for patients with

83 Chemerin is a potent chemoattractant for cells expressin

84 Chemerin is a proinflammatory plasma protein that binds

85 le known ligand for CMKLR1, and we show that chemerin is activated during blood coagulation and attra

86 We show that Chemerin is expressed in cultured DE progenitor cells, w

87 The bioactivity of chemerin is post-translationally regulated; the attracta

88 Chem158K was the dominant chemerin isoform, and it was not generated by ex vivo pr

89 logy for production of different recombinant chemerin isoforms (chem163S, chem157S, and chem155A) whi

90 To identify and quantify the in vivo chemerin isoforms in biological specimens, we developed

91 eptides from the C terminus of the different chemerin isoforms.

92 ion-dependent fashion, regulates circulating chemerin levels and its bioactivity, and enhances chemer

93 Elevated serum chemerin levels correlate with increased severity of pol

94 ontal therapy influenced the decrease of GCF chemerin levels in patients with CP with and without t2D

95 Furthermore, it suggests GCF chemerin levels may be considered a potential proinflamm

96 t of non-surgical periodontal therapy on GCF chemerin levels.

97 e regulation, where the inflammatory signal, chemerin, links TH and RA signaling to hypothalamic remo

98 igenesis and suggest that down-regulation of chemerin may be an important mechanism of tumor immune e

99 eptides possess antiinflammatory properties, chemerin may be involved in both the initiation and reso

100 We conclude that CMKLR1 expression and chemerin-mediated chemotaxis distinguish circulating pDC

101 Moreover, high chemerin messenger RNA expression in tumors correlated w

102 In silico analysis showed chemerin mRNA was significantly increased in tissue from

103 By contrast, acute ICV bolus injection of chemerin on a 12 h:12 h photoperiod inhibited food intak

104 ingly, activated endothelial cells expressed chemerin on the plasma membrane and promoted in a more e

105 r, TAFIa) enhanced the bioactivity of 10-mer chemerin peptide NH(2)-YFPGQFAFSK-COOH by removing the c

106 ptor 1 (BLT1) antagonist U-75302, but not by chemerin peptide, a ligand specific for another RvE1 rec

107 PMN exposure to RvE1 or chemerin (peptide agonist of ChemR23) reduced transepith

108 We demonstrate that murine chemerin possesses potent antiinflammatory properties th

109 Visfatin, chemerin, progranulin, interleukin (IL)-1beta, IL-8, MMP

110 addition, we discovered that platelets store chemerin protein and release it upon stimulation.

111 een identified as an additional receptor for chemerin, providing a unique mechanism by which chemerin

112 Gene expression of chemerin (Rarres2) and its receptors were localised with

113 The goal of this study was to investigate Chemerin (Rarres2)/ChemR23(Cmklr1) signaling in DE-DM ce

114 The chemerin receptor (CMKLR1) is a G protein-coupled recept

115 sion and inflammation via the cell-signaling chemerin receptor CMKLR1.

116 U-87 MG cells, a human GBM line, express the chemerin receptors, chemokine-like receptor 1 and chemok

117 lipid and peptide agonists, resolvin E1 and chemerin, respectively.

118 only those identical to specific C-terminal chemerin sequences exerted antiinflammatory effects at p

119 When tested in vivo, a chemerin SMAL decreased allergic airway inflammation and

120 Finally, chemerin stimulation of myeloid dendritic cells induced

121 Chemerin, the ChemR23 ligand, was detected by immunohist

122 mmon binding site that overlaps with that of chemerin, the natural ligand of ChemR23.

123 olayers through the endogenous production of chemerin, the upregulation of CCRL2, and the activation

124 d increase local concentrations of bioactive chemerin, thus providing a link between CCRL2 expression

125 nsignaling receptor able to bind and present chemerin to ChemR23(+) dendritic cells.

126 tudy provides the first direct evidence that chemerin undergoes extensive proteolytic processing in v

127 The inhibition was partial when chemerin was used as agonist and complete when the cheme

128 On the other hand, the fraction of cleaved chemerins was much higher in synovial fluid and cerebros

129 expressing M1 macrophages are chemotactic to chemerin, whereas M2 macrophages not expressing ChemR23

130 These results show that chemerin, whether expressed by tumor cells or within the

131 stically significant positive correlation of chemerin with IL-6, glycated hemoglobin, sampled-site cl